MAX BioPharma
Private Company
Funding information not available
Overview
MAX BioPharma is a preclinical biotech leveraging its proprietary Oxysterol Therapeutics® platform to develop small-molecule lipid drugs. Founded on discoveries from UCLA, the company's most advanced candidate, Oxy210, is an oral, antifibrotic/anti-inflammatory agent being developed for MASH. As a private, preclinical-stage company, MAX BioPharma is targeting large, unmet medical needs across fibrosis, inflammation, and infection, but faces the inherent risks of early-stage drug development and platform validation.
Technology Platform
Oxysterol Therapeutics®: A proprietary drug discovery platform based on synthetic, small-molecule oxysterols that modulate cellular signaling pathways (e.g., Hedgehog) to treat diseases in fibrosis, inflammation, infection, and bone disorders.
Opportunities
Risk Factors
Competitive Landscape
In MASH, competition is intense with numerous large pharma and biotech companies in late-stage clinical trials. The fibrosis and IPF landscapes also have approved and late-stage therapies. MAX BioPharma's differentiation lies in its novel mechanism of action via oxysterols, but it trails significantly in development stage.